(Q37732629)

22 August 2017

Ovarian cancer in the elderly: outcomes with neoadjuvant chemotherapy or primary cytoreduction (English)

1 reference

22 August 2017

1 reference

1 reference

neoadjuvant chemotherapy

1 reference

2

Chirag A Shah

1 reference

22 August 2017

Kate A McLean

1

1 reference

22 August 2017

Sara A Thompson

3

1 reference

22 August 2017

Heidi J Gray

4

1 reference

22 August 2017

Ron E Swensen

5

1 reference

22 August 2017

Barbara A Goff

6

1 reference

22 August 2017

language of work or name

English

0 references

publication date

27 April 2010

1 reference

22 August 2017

1 reference

22 August 2017

118

1 reference

22 August 2017

1

1 reference

22 August 2017

43-46

1 reference

Ovarian cancer in the elderly: an analysis of Surveillance, Epidemiology, and End Results Program data

22 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.002

The role of neoadjuvant chemotherapy in the treatment of advanced ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.002

Participation of patients 65 years of age or older in cancer clinical trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.002

Treatment patterns by decade of life in elderly women (> or =70 years of age) with ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.002

Variations in the Use of Chemotherapy for Elderly Patients With Advanced Ovarian Cancer: A Population-Based Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.002

Ovarian cancer in the octogenarian: does the paradigm of aggressive cytoreductive surgery and chemotherapy still apply?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.002

Management of ovarian cancer in patients older than 80 years of Age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.002

Treatment of advanced ovarian carcinoma in the elderly.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.002

Surgical care of elderly women with ovarian cancer: a population-based perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.002

Ovarian cancer. Survival and treatment differences by age

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.002

Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.002

Predictors of surgical outcome and survival among elderly women diagnosed with ovarian and primary peritoneal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.002

Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.002

Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.002

Secondary surgical cytoreduction for advanced ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.002

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.002

Epithelial ovarian cancer in the elderly. The Memorial Sloan-Kettering Cancer Center experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.002

inferred from DOI database lookup

7 January 2021

based on heuristic

Analysis of patient age as an independent prognostic factor for survival in a phase III study of cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in stages III (suboptimal) and IV ovarian cancer. A Southwest Oncology Group study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.002

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YGYNO.2010.03.002

1 reference

22 August 2017

1 reference